Associated Papers
BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy.
Pattalachinti VK et al.
Npj Precision Oncology, 2025
39910160 (PubMed )
Supplement: 41698_2025_821_MOESM1_ESM.pdf
Rare Single Nucleotide and Copy Number Variants and the Etiology of Congenital Obstructive Uropathy: Implications for Genetic Diagnosis.
Ahram DF et al.
Journal of the American Society of Nephrology : Jasn, 2023
Case report: targeted sequencing improves the diagnosis of multiple synchronous lung cancers.
Ba Y et al.
Translational Lung Cancer Research, 2023
Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone Treatment.
Sicotte H et al.
Molecular Cancer Research : Mcr, 2022
Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.
Dankner M et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2018
Structural analysis of missense mutations in galactokinase 1 (GALK1) leading to galactosemia type-2.
P S et al.
Journal of Cellular Biochemistry, 2018
Copy number signatures and mutational processes in ovarian carcinoma.
Macintyre G et al.
Nature Genetics, 2018
30104763 (PubMed )
Supplement: NIHMS78219-supplement-3.xlsx › mutated_cases
Select a paper to view details